Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AbbVie, Jacobio Pharma Enter Strategic Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

AbbVie, Jacobio Pharma Enter Strategic Pact

To develop and commercialize SHP2 inhibitors targeting a key node in cancer and immune cells.

By: Contract Pharma

Contract Pharma Staff

AbbVie and Jacobio Pharmaceuticals have entered a global, strategic collaboration to develop and commercialize SHP2 inhibitors targeting a key node in cancer and immune cells.

SHP2 is a key protein mediator of cellular signaling through RAS/MAP kinase pathway. Many tumors have genetic mutations, driving abnormal cancer cell growth which relies on SHP2 activity.
SHP2 also plays a key role to control cytokine production and immune cell response. Therefore, inhibition of SHP2 is believed to have dual effects by potentially reducing cancer cell growth and modulating immune responses to generate anti-tumor activities. Jacobio’s early clinical stage SHP2 assets, JAB-3068 and JAB-3312, are oral small molecules designed to specifically inhibit SHP2activity.

AbbVie will be granted an exclusive license to the SHP2 portfolio. Jacobio will continue to conduct early global clinical trials of JAB-3068 and JAB-3312 with AbbVie covering R&D expenses. Upon completion, AbbVie will assume global development and commercialization responsibilities. Jacobio has an option to exclusively develop and commercialize the SHP2 program in China, Hong Kong, and Macau. Financial terms were not disclosed.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics